What is a GnRH (gonadorelin) stimulation test?

It is a diagnostic test in which gonadorelin is given and LH/FSH are measured over time to assess how the pituitary-gonadal axis responds, aiding evaluation of puberty and pituitary disorders.

Why does gonadorelin have to be given in pulses?

The pituitary responds to intermittent GnRH pulses. Continuous exposure desensitizes GnRH receptors and actually suppresses LH and FSH, which is the basis for long-acting GnRH-agonist drugs.

Is gonadorelin approved by regulators?

Gonadorelin has been approved in various markets for diagnostic testing and, historically, for pulsatile treatment of hypogonadotropic hypogonadism, though availability differs by country and over time.

Is gonadorelin used for bodybuilding or post-cycle recovery?

Such uses are not supported by the clinical evidence base, which centers on diagnostic testing and treatment of hypogonadotropic hypogonadism and infertility. Any use should be directed by a physician.

EMA-approvedaka GnRH, LHRH, Factrel, Lutrepulse

Gonadorelin — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Gonadorelin (also known as GnRH) is a peptide catalogued under Sexual Health (GnRH). It is described as: GnRH receptor. Documented context: Hypothalamic amenorrhea; diagnostic. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Gonadorelin?

Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH), the native decapeptide that drives pituitary release of LH and FSH.

It is an approved drug in several markets, used diagnostically as a GnRH stimulation test and historically delivered by pulsatile pump to treat hypogonadotropic hypogonadism and induce ovulation or spermatogenesis.

Evidence in humans is well established for these endocrine indications, though pulsatile GnRH has largely been supplanted by gonadotropin therapy in routine practice.

How does Gonadorelin work?

Given in physiologic pulses, gonadorelin binds pituitary gonadotroph GnRH receptors to stimulate LH and FSH secretion.

Continuous (non-pulsatile) exposure instead desensitizes the receptor and suppresses gonadotropins, which is the basis for long-acting GnRH-agonist drugs.

What does the research say about Gonadorelin?

Pulsatile GnRH can induce ovulation in women with hypogonadotropic hypogonadism. ^[2]
Pulsatile GnRH therapy can restore gonadotropin secretion and fertility in congenital hypogonadotropic hypogonadism. ^[1]
A GnRH (gonadorelin) stimulation test helps evaluate pubertal and pituitary-gonadal axis disorders via the peak LH response. ^[4]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Clinical Management of Congenital Hypogonadotropic Hypogonadism — Young J et al., Endocrine Reviews 2019. (Review)
[2] Pulsatile GnRH therapy for the induction of ovulation in hypogonadotropic hypogonadism — Blunt SM et al., Acta Endocrinologica. Supplementum 1988. (Clinical study)
[3] Predictive factors for pituitary response to pulsatile GnRH therapy in patients with congenital hypogonadotropic hypogonadism — Mao JF et al., Asian Journal of Andrology 2018. (Clinical cohort)
[4] Diagnostic utility of the average peak LH levels measured during GnRH stimulation test — Koca SB et al., Journal of Pediatric Endocrinology and Metabolism 2024. (Diagnostic study)
[5] LH and FSH responses to GnRH in health and disease — Dash RJ et al., Journal of Steroid Biochemistry 1985. (Review)
[6] Inducing puberty — Delemarre EM et al., European Journal of Endocrinology 2008. (Review)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

In clinical use, diagnostic testing employs a single intravenous bolus with timed LH/FSH sampling, while therapeutic use historically involved small subcutaneous or intravenous pulses every 60 to 120 minutes via pump.

These are context-only descriptions of published clinical protocols, not dosing guidance for personal use.

Side effects & safety profile

As a short-acting diagnostic or pulsatile agent, gonadorelin is generally well tolerated; reported effects include injection-site reactions and, rarely, hypersensitivity.

Pulsatile administration requires a programmable infusion pump and specialist supervision.

This is a prescription hormone; self-administration outside medical care is not appropriate and dosing must be individualized by a clinician.

Stacking & combinations

In fertility protocols gonadorelin has been used as an alternative to, not alongside, exogenous gonadotropins (hCG/FSH), which act downstream at the gonad.

Finding Gonadorelin vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

Yes. Gonadorelin is the synthetic form of natural gonadotropin-releasing hormone (GnRH), the hypothalamic decapeptide that signals the pituitary to release LH and FSH.

References

[1] Clinical Management of Congenital Hypogonadotropic Hypogonadism — Young J et al., Endocrine Reviews 2019. PMID: 30698671. View sourceStudy: ReviewReviews pulsatile GnRH and gonadotropin approaches to restore puberty and fertility in congenital hypogonadotropic hypogonadism.
[2] Pulsatile GnRH therapy for the induction of ovulation in hypogonadotropic hypogonadism — Blunt SM et al., Acta Endocrinologica. Supplementum 1988. PMID: 3138867. View sourceStudy: Clinical studyPulsatile GnRH successfully induced ovulation in women with hypogonadotropic hypogonadism.
[3] Predictive factors for pituitary response to pulsatile GnRH therapy in patients with congenital hypogonadotropic hypogonadism — Mao JF et al., Asian Journal of Andrology 2018. PMID: 29516878. View sourceStudy: Clinical cohortIdentifies baseline factors predicting gonadotropin and testicular response to pulsatile GnRH in men.
[4] Diagnostic utility of the average peak LH levels measured during GnRH stimulation test — Koca SB et al., Journal of Pediatric Endocrinology and Metabolism 2024. PMID: 39163851. View sourceStudy: Diagnostic studyEvaluates peak LH on the GnRH stimulation test as a diagnostic marker in pubertal assessment.
[5] LH and FSH responses to GnRH in health and disease — Dash RJ et al., Journal of Steroid Biochemistry 1985. PMID: 3935867. View sourceStudy: ReviewDescribes LH/FSH secretory responses to GnRH stimulation across physiologic and pathologic states.
[6] Inducing puberty — Delemarre EM et al., European Journal of Endocrinology 2008. PMID: 18796540. View sourceStudy: ReviewDiscusses pulsatile GnRH and gonadotropins among strategies to induce puberty in hypogonadotropic patients.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.